联系方式：yincq@szbl.ac.cn
课题组主要研究方向为代谢重编程和蛋白翻译后修饰在恶性肿瘤发生发展中的调控机制，综合运用蛋白质多组学、代谢组学、肿瘤生物学、基因编辑工程和高通量筛选等技术手段，结合临床样本以及肿瘤类器官和动物模型，揭示癌症发生发展的关键代谢和信号通路，以挖掘癌症治疗新靶点和开发治疗新策略。
国家级高层次人才（青年）
深圳市海外高层次人才（B类）
美国国立卫生研究院K99/R00 Pathway to Independence Award
美国癌症研究协会AACR Scholar-in-Training Award
中国细胞生物学学会细胞工程与转基因生物分会委员
深圳市免疫学会理事
尹成骞博士，深圳湾实验室特聘研究员，博士生导师，国家级高层次人才（青年），深圳市海外高层次人才。近年来主要从事癌症发生发展的机制研究以及针对癌症预防和治疗的药物开发，研究成果以第一作者发表在Cell和Nature，以通讯作者发表在Journal of Experimental Medicine，EMBO J，Nature Communications （2024，2025）、Trends in Cell Biology，Advanced Science等国际知名期刊。主持项目包括国家自然科学基金海外优秀青年基金项目和青年基金项目、深圳市医学研究专项资金项目以及美国国立卫生研究院K99/R00 Pathway to Independence项目等，以核心成员参与国家重点研发计划和国自然专项项目，获授权美国专利一项和国内专利两项。
近年来主要科学贡献包括：(1) 阐释G蛋白偶联受体MC1R和谷胱甘肽过氧化物酶GPX4的棕榈酰化修饰调控恶性肿瘤发生发展的分子机制 (Nature, 2017；Cancer Research，2023；Nature Communications，2025)；(2) 揭示RAS/RAF突变肿瘤发生发展所依赖的共性信号通路 (Cell，2019；Nature Communications，2024；Journal of Experimental Medicine，2025)；(3) 揭示和探讨了代谢通路调控细胞铁死亡的分子机制，为靶向代谢癌症治疗策略的开发提供新的靶标 (Advanced Science，2023；Trends in Cell Biology，2024；EMBO Journal，in press)。
1. SLC25A1 and ACLY maintain cytosolic acetyl-CoA to regulate ferroptosis susceptibility via FSP1 acetylation. EMBO Journal. Li, W.#, Han, J.#, Huang, B. #, Xu, T. #, Wan, Y., Luo, D., Kong, W., Yu, Y., Zhang, L., Nian, Y. *, Chu, B. *, Yin, C. * 2025, in press
2. PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers. Journal of Experimental Medicine. 222(3): e20241147. He, Y.#, Li, W.#, Zhang, M. #, Wang, H., Lin, P., Yu, Y., Huang, B., Hao, M., He, J., Kong, W., Luo, D., Xu, T., Wang, J., Huang, Y., Zhao, Q., Liu, Y., Zhang, J., Nian, Y., Zhang, L., Zhu, B., Yin, C.* 2025/01. DOI:10.1084/jem.20241147
3. Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis. Nature Communications. 16: 867. Huang, B.#, Wang, H.#, Liu, S.#, Hao, M.#, Luo, D., Zhou, Y., Huang, Y., Nian, Y., Zhang, L., Chu, B., Yin, C.* 2025/01. DOI:10.1038/s41467-025-56344-5
4. Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma. Nature Communications. 15, 10088. Wen, Y.#, Wang, H.#, Yang, X.#, Zhu, Y., Li, M., Ma, X., Huang, L., Wan, R., Zhang, C., Li, S., Jia, H., Guo, Q., Lu, X., Li, Z., Shen, X., Zhang, Q.*, Si, L.*, Yin, C.*, Liu, T*. 2024/11.
5. Gut microbial metabolism in ferroptosis and colorectal cancer. Trends in Cell Biology. 10(11), Cui, W.#, Hao, M.#, Yang, X.*, Yin, C.*, Chu, B*. 2024/08.
6. Tryptophan metabolism acts as a new anti-ferroptotic pathway to mediate tumor growth. Advanced Science. 10(6), 2204006. Liu, D.#, Liang, C.#, Huang, B.#, Zhuang, X., Cui, W., Yang, L., Yang, Y., Zhang, Y., Fu, X., Zhang, X., Du, L., Gu, W., Wang, X., Yin, C.*, Chai, R.*, Chu, B.* 2023/02.
7. Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis. Clinical Immunology. 252023, 0, 109294. Liu, L. #, Zhou, Y. #, Luo, D. #, Sun, X., Li, H., Lu, Y., Wang, J., Zhang, M., Lin, N., Yin, C.*, Li, X.*, 2023/01.
8. AMPK phosphorylates ZDHHC13 to increase MC1R activity and suppress melanomagenesis. Cancer Research. 83 (7): 1062–1073. Sun, Y.#, Li, X.#, Yin, C.#, Zhang, J., Liang, E., Wu, X., Ni, Y., Arbesman, J., Goding, C. R., Chen, S. 2023/01
9. Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis. Cell. 176(5), 1113-1127. Yin, C.#, Zhu, B.#, Zhang, T.#, Liu, T.#, Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., Zhang, J., Li, L., Wei, G., Xu, Z., Gao, X., Huang, C., Wei, Z., Goding, C. R., Wang, P.*, Deng, X.*, Cui, R.* 2019/02
10. Palmitoylation-dependent activation of MC1R prevents melanomagenesis. Nature. 549(7672), 399-403. Chen, S.#, Zhu, B.#, Yin, C.#, Liu, W., Han, C., Chen, B., Liu, T., Li, X., Chen, X., Li, C., Hu, L., Zhou, J., Xu, Z., Gao, X., Wu, X., Goding, C. R., Cui, R. 2017/09
